Sun Pharma Advanced Research Company Limited (SPARC.NS)
- Previous Close
315.95 - Open
300.15 - Bid --
- Ask --
- Day's Range
300.15 - 300.15 - 52 Week Range
178.80 - 472.80 - Volume
104,142 - Avg. Volume
281,002 - Market Cap (intraday)
97.729B - Beta (5Y Monthly) 0.74
- PE Ratio (TTM)
-- - EPS (TTM)
-11.34 - Earnings Date May 20, 2024 - May 24, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1,282.00
Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, dermatology, and Immunology. The company offers Elepsia XR, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension; and Phenobarbital injection for the treatment of neonatal seizures. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. The company was incorporated in 2006 and is based in Mumbai, India.
www.sparc.life407
Full Time Employees
March 31
Fiscal Year Ends
Sector
Related News
Performance Overview: SPARC.NS
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SPARC.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SPARC.NS
Valuation Measures
Market Cap
102.87B
Enterprise Value
99.23B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
95.90
Price/Book (mrq)
30.91
Enterprise Value/Revenue
93.02
Enterprise Value/EBITDA
-28.35
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
1.07B
Net Income Avi to Common (ttm)
-3.63B
Diluted EPS (ttm)
-11.34
Balance Sheet and Cash Flow
Total Cash (mrq)
3.66B
Total Debt/Equity (mrq)
4.28%
Levered Free Cash Flow (ttm)
--
Research Analysis: SPARC.NS
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: SPARC.NS
SPARC.NS does not have Company Insights